Tag: Food and Drug Law ⋅ Page 1

Professor Lietzan Presents Paper at Law and Biosciences Workshop

On May 6, Professor Erika Lietzan presented her most recent paper at Stanford Law School, as part of its Law and the Biosciences Workshop. Her paper, Access Before Evidence and the Price of FDA’s New Drug Authorities, explores the costs of error and delay associated with federal government approval of new drugs, as well as costs associated with other less-studied aspects of…

Professor Lietzan Speaks About Top Cases in Food and Drug Law

On May 3, Professor Erika Lietzan spoke at the annual meeting of the Food and Drug Law Institute (FDLI), a nonprofit organization dating to the 1940s that brings together experts from the federal government, industry, the private bar, non-profit organizations, patient and consumer advocates, consulting firms, and academia. Its annual meeting is the premier conference for the food and drug law community…

Professor Lietzan Quoted by CBS News on Pharmaceutical Manufacturing Recall

Professor Erika Lietzan was recently quoted by CBS News in a Moneywatch article relating to pharmaceutical manufacturing, “Drugmaker behind ibuprofen recall has history of FDA violations.” Last month New Jersey drugmaker Tris Pharma doubled its recall of infant ibuprofen, and CBS News spoke with Professor Lietzan about the company’s manufacturing history.  She described some of the “red flags” in a…

Professor Lietzan Collaborates on Compassionate Use Research in France and the U.S.

Professor Erika Lietzan is spending six weeks in France at the invitation of the Centre de Recherche sur le Droit International des Marchés et des Investissements (CREDIMI) at Université de Bourgogne. At the end of November, she attended a colloquium at the French Supreme Court concerning the rights of children with anonymous biological parents (due to sperm or egg donation) to learn the identities…

Professor Lietzan Speaks at Food & Drug Law Institute’s Annual Conference

On May 4, Professor Erika Lietzan participated in the perennially popular closing session – on significant litigation in 2017 and cases to watch in 2018 – of the Food & Drug Law Institute’s annual conference.  FDLI is the primary professional association for specialists in food and drug law.  The annual meeting brought together more than 900 law professors, practicing lawyers,…

Professor Lietzan Participates in Center for the Protection of Intellectual Property Summer Institute

Professor Erika Lietzan recently attended the 2017 Summer Institute, hosted by the Center for the Protection of Intellectual Property at Antonin Scalia Law School, George Mason University. She presented “The Drug Innovation Paradox,” which will be published by the Missouri Law Review next year, explains that the United States has chosen to incentivize drug innovation with a period of exclusive…

Professor Lietzan Files Amicus Brief with U.S. Supreme Court in Patent Case

Professor Lietzan recently filed an amicus brief in the United States Supreme Court, in a closely-watched case involving patent litigation under the Biologics Price Competition and Innovation Act (BPCIA). The appellate court concluded that biosimilar applicants may elect not to comply with the information exchange provisions laid out in the statute, effectively opting out of the statutory premarket patent litigation…